Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bayard Powell

Medical Oncology Winston Salem, NC Medical Doctor

NPI 1831173954 CMS profile 83151

Medical Center Blvd, Winston Salem, NC 27157

Open in the dashboard

General payments

$18,589

27 records reported · program years 2019–2025

Research payments

$223

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,570,468 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Bayard Powell of Winston Salem, NC is reported in the CMS Open Payments database as having received $18,589 across 27 general payments and $223 in research payments paid to them. Separately, studies naming them as principal investigator received $3,570,468 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,550 1
2025 Research $223 1
2024 General $994 4
2023 General $70 1
2021 General $128 1
2020 General $633 2
2019 General $14,215 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bayard Powell
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Bayard Powell were reported at $2,550. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Bayard Powell Medical Oncology median Middle half National median
2019 $14,215 $968 $140–$6,658 $163
2020 $633 $747 $102–$5,891 $114
2021 $128 $430 $50–$4,098 $132
2022 $0 $812 $127–$4,907 $149
2023 $70 $957 $144–$5,248 $160
2024 $994 $1,042 $149–$5,650 $164
2025 $2,550 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $10,034 11 payments
  2. Pfizer Inc. $4,282 5 payments
  3. Novartis Pharmaceuticals Corporation $3,544 5 payments
  4. F. Hoffmann-La Roche AG $393 2 payments
  5. Seattle Genetics, Inc. $170 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $83 1 payment
  7. Genentech USA, Inc. $83 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $9,851 5 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,063 4 payments
  3. Travel and Lodging $1,397 5 payments
  4. Food and Beverage $910 7 payments
  5. Education $367 6 payments
Products named General payments · program years 2019–2025
  1. VYXEOS Oncology $9,356 9 payments
  2. BOSULIF $4,251 3 payments
  3. VYXEOS Hematology/Oncology $678 2 payments
  4. VENCLEXTA $393 2 payments
  5. RYLAZE $128 1 payment
  6. DEFITELIO $128 1 payment
  7. VELCADE $83 1 payment
  8. TECENTRIQ $83 1 payment
  9. MYLOTARG $20 1 payment
  10. BESPONSA $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $223 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Hematology-Oncology: 604

Drug cost

$8,180

Median for Hematology-Oncology: $1,306,514

Branded share of claims

0%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Posaconazole Generic 11 $8,180

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$31,801

Medicare's payments for the services billed

Medicare patients

98

Average age 73

Services billed

458

39 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%
Atrial fibrillation 35%
Diabetes 34%
Chronic kidney disease 30%
Ischemic heart disease 24%
Heart failure 23%
Cancer 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record